Scientific Publications

2023

TransportNPC: A Phase 3 Global Trial of Trappsol® Cyclo™ Administered Intravenously to Patients with Niemann-Pick Disease Type C1 (NPC1)

          Authors: Joseph Mejia, MD / Lise Kjems, PhD, MD / Rebecca Fine / Caroline Hastings, MD

 

2022

 Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial

          Authors: Caroline Hastings, MD / Benny Liu, MD / Bryan Hurst / Gerald F. Cox, MD, PhD / Sharon Hrynkow, PhD

 

Intravenous Trappsol® Cyclo™in patients with Niemann Pick Disease type C1: Updates on the Results from Phase I and Phase I/II studies and launch of the international Phase III pivotal Transport NPC trial

      • NNPDF/INPDA Annual Meeting, Orlando, FL
      • Caroline Hastings, MD / Lise Kjems, MD, PhD
      • July 30, 2022

From Bench to Bedside – A Review of the Trappsol® Cyclo™ Program for the Treatment of Niemann Pick Disease Type C

      • World Orphan Drug Congress USA 2022
      • Lise Kjems, MD, PhD
      • July 13, 2022

    2021

    Topline Results from Phase 1/2 Study to Evaluate Safety and Efficacy of Intravenous Trappsol® Cyclo™ in Patients with Niemann-Pick Type C1 Disease

        • Australian NPC Disease Foundation Annual Conference
        • Julian Raiman, MD
        • June 25, 2021
      Results from Phase 1 study to evaluate the single- and multiple-dose pharmacokinetics of Intravenous Trappsol® Cyclo ™ in patients with Niemann Pick Disease type C1 and the Effects of Dosing upon Biomarkers of NPC Disease

          • Australian NPC Disease Foundation Annual Conference
          • Caroline Hastings, MD
          • June 25, 2021

        Phase 3 Study to Evaluate Intravenous Trappsol® Cyclo™ Versus Placebo in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

            • Australian NPC Disease Foundation Annual Conference
            • Gerald Cox, MD, PhD
            • June 25, 2021
          A phase I/II Study to Evaluate the Safety and Pharmacokinetics of Intravenous Trappsol® Cyclo™ Versus Placebo in Patients With Niemann-Pick Disease Type C (NPC1) and the Pharmacodynamic Effects of Treatment upon Markers of Cholesterol Metabolism and Clinical Outcomes (NCT02912793)

              • WORLDSymposium presentation
              • Julian Raiman, MD
              • Feb 9, 2021

            Update on Phase 1 study to evaluate the single- and multiple-dose pharmacokinetics of intravenous hydroxypropyl betacyclodextrin (HPβCD) in patients with Niemann-Pick disease type C (NPC-1) and the effects of dosing upon biomarkers of NPC disease (NCT02939547)

              • WORLDSymposium presentation
              • Caroline Hasting, MD
              • Feb 9, 2021

            2020

            Interim Analysis of Phase I/II Trial with Trappsol® Cyclo™ Delivered Intravenously in NPC Patients

              • NNPDF Presentation
              • Julian Raiman, MD
              • Jul 9, 2020

            Top Line Results of Phase I Intravenous Trial for NPC

              • NNPDF Presentation
              • Caroline Hasting, MD
              • Jul 9, 2020
            Our Clinical Studies
            Our Pipeline
            Sign up for Alerts

            Trappsol® Cyclo™ is not currently approved for any indication.

            Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.